Daclizumab to Prevent Rejection after Cardiac Transplantation - Daclizumab to Prevent Rejection after Cardiac Transplantation

Description:

The goal of the trial was to evaluate treatment with daclizumab, a humanized monoclonal antibody against the interleukin-2 receptor, compared with placebo among patients undergoing first cardiac transplantation.